Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes caused every listed death or that the same fractions apply today.

Which denominator belongs to each figure?

Gelgoot and colleagues used Ontario coroner data for opioid deaths, with Toronto as a geographic subset. The numerator counts deaths in which a nitazene was present. The denominator counts opioid deaths in that jurisdiction and period. The study also analyzed drug-checking and police-seizure samples from January 2019 to July 2024. Those analytical submissions have a different selection process and a later endpoint; their percentages should not be mixed with the death fractions.

What does “present” establish?

It reports detection in the death data. It does not assign a sole cause of death, dose, timing or role relative to other substances for each person. The study describes co-occurring drugs in submitted material and uses separate data streams to examine broader market patterns. A specific death requires its autopsy, full toxicology, circumstances and medical findings.

Why not generalize the percentage?

The figures concern a defined period and jurisdiction. Testing panels, drug-market composition and case ascertainment can change. Ontario’s 0.91% and Toronto’s 1.83% are not national prevalence figures, and neither describes the proportion of all opioid users exposed to nitazenes. The correct statement keeps the place, time and opioid-death denominator attached.

The study shows that nitazenes appeared in some opioid-death investigations during that interval. It does not support a claim that they were present in most such deaths or establish their role in a particular case without its underlying records.

Scientific source

Gelgoot EA, Scarfone KM, Maghsoudi N, et al. The Detection of Novel Nitazene-Class Opioids in Unregulated Drug Markets in Canada. Drug and Alcohol Review. 2026;45:e70189. doi:10.1111/dar.70189. Based on the supplied full paper.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Short answer: Detecting an unexpected opioid at trace level does not, by itself, establish that a product contained an active adulterating dose. In a British Columbia drug-checking study, 189 of 8,889 samples not expected to include fentanyl had an unexpected opioid, and 61.4% of those detections were at trace concentration….

Spread the love

Read Article: Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes…

Spread the love

Read Article: Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Why a GHB Result May Not Identify the Substance Originally Taken

Short answer: A test that reports GHB does not necessarily identify the substance a person originally took. A scientific review by Busardò and Jones explains that gamma-butyrolactone (GBL) and 1,4-butanediol can convert rapidly to GHB after ingestion. The measured GHB is a real analytical finding, but the starting compound is…

Spread the love

Read Article: Why a GHB Result May Not Identify the Substance Originally Taken

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us